Rupee at 93/USD: IT & Pharma Stocks Set for Margin Revival
Currency depreciation triggers FII exodus but creates tailwinds for export-heavy sectors
market · 21 March 2026 · 4 min read
Currency Crisis Creates Sectoral Divergence
The Indian rupee's breach of the 93-per-dollar psychological barrier marks a watershed moment for equity markets, with the currency touching an all-time low of 92.48-93 against the greenback. This 2.8% decline over the past month has coincided with India's benchmark 10-year government bond yield surging by 18 basis points in its steepest weekly climb since mid-September, signaling broader financial market stress.
The rupee's weakness has accelerated foreign institutional investor (FII) selling, with net outflows crossing ₹1.2 lakh crore in recent months. However, this currency depreciation is creating a clear sectoral bifurcation in the equity markets, particularly benefiting export-oriented industries that derive substantial revenue in dollar terms.
IT Sector: The Primary Beneficiary
Information Technology stocks are experiencing a structural tailwind from rupee depreciation, with every 1% currency weakness typically translating to 40-50 basis points of operating margin expansion for major players. NSE: TCS, India's largest IT services company with 95% revenue from overseas markets, stands to gain approximately ₹800-1,000 crore in additional annual revenue for every rupee of depreciation.
NSE: INFY and NSE: WIPRO, both generating over 85% of their revenues from international markets, are witnessing similar margin benefits. Infosys's recent guidance revision factors in currency tailwinds, with management indicating that sustained rupee weakness could boost FY25 margins by 150-200 basis points. NSE: HCLTECH and NSE: TECHM are also positioned favorably, particularly given their exposure to European and North American markets where billing rates remain firm in local currency terms.
The sector's FairStock Scores have shown improvement, with several large-cap IT stocks now trading above 75, indicating strong fundamental resilience despite global economic uncertainties.
Pharmaceutical Exports Gain Momentum
The pharmaceut...
AI-generated market intelligence. Not investment advice.